# Voyager Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/voyager-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.voyagertherapeutics.com
- Total disclosed funding: $85M
- Latest round: Series B (Apr 13, 2015)
- Investors on record: 5

## About

Voyager Therapeutics specializes in innovative gene therapies for neurological diseases, utilizing advanced delivery systems to enhance treatment efficacy and improve patient outcomes in areas such as Alzheimer's and Parkinson's disease.Founded in 2014, Voyager Therapeutics is based in Cambridge, US, and focuses on developing genetic medicines to treat neurological disorders. The company has undergone strategic pivots to enhance its product offerings and has raised a total of USD 70 mn through funding rounds, with the latest being an IPO on November 10, 2015. The company was co-founded by Steve Paul, a notable figure in the biotech sector, and is currently led by CEO Al Sandrock.Voyager Therapeutics is focused on the development of innovative gene therapies aimed at treating a range of neurological diseases. The company’s primary product offerings include genetic medicines targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other central nervous system disorders. These therapies utilize the TRACER™ (Translationally-Optimized AAV Capsid Engineering) platform, which enables the creation of novel AAV capsids designed for efficient delivery across the blood-brain barrier. The end users of these therapies are primarily patients suffering from these debilitating conditions, while the company collaborates with various healthcare providers and research institutions to bring these products to market. Voyager Therapeutics operates primarily in North America and Europe, focusing on regions with a high prevalence of neurological disorders.In the most recent year, Voyager Therapeutics reported a revenue of USD 80.00 mn for 2024, alongside an EBITDA of USD -70.59 mn. The company generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations, which include milestone payments and royalties from product sales. Their flagship product, VY7523 for Alzheimer’s disease, is expected to contribute significantly to these financial arrangements as it advances through clinical trials.Voyager Therapeutics plans to leverage recent funding of USD 70 mn raised during their IPO to further develop their pipeline of gene therapies, particularly focusing on VY7523 for Alzheimer’s disease and expanding their product offerings. The company aims to launch new products aimed at treating various neurological disorders in the coming years. Additionally, Voyager Therapeutics is actively exploring opportunities to expand into new geographic markets, particularly targeting Europe and Asia, with initiatives expected to commence within the next 2 years.

## Funding rounds

- Series B, Apr 13, 2015, $60M — Wellington Management, Casdin Capital, Brookside Capital, Partner Fund Management
- Series A, Feb 12, 2014, $25M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Brookside Capital — Series B
- Partner Fund Management — Series B